Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 21;31(12):8094-8109.
doi: 10.3390/curroncol31120596.

Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia

Ruah Alyamany  1 , Ahmed Alnughmush  1 , Hazzaa Alzahrani  1 , Mansour Alfayez  1
Affiliations
Review

Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia

Ruah Alyamany et al. Curr Oncol. .

Abstract

Chemotherapy-induced cytopenia (CIC) is characterized by neutropenia, anemia, and thrombocytopenia, which are common and serious complications in cancer treatment. These conditions affect approximately 60% of patients undergoing chemotherapy and can significantly impact quality of life, treatment continuity, and overall survival. The use of growth factors, including granulocyte colony-stimulating factors (GCSFs), erythropoietin-stimulating agents (ESAs), and thrombopoietin receptor agonists (TPO-RAs), has emerged as a promising strategy for managing CIC. However, the use of these growth factors must be approached with caution. This review provides an overview of the mechanisms, efficacy, and safety of growth factors in the management of CIC. Additionally, we discuss predictive markers for treatment response, potential risks, and highlight areas for future research.

Keywords: adverse effects; chemotherapy-induced cytopenia; cytopenia; growth factors.

PubMed Disclaimer

Conflict of interest statement

M.A.: Honoraria: Johnson & Johnson, Pfizer, Astellas, Novartis, Amgen, AstraZeneca, AbbVie, Advisory board: Johnson & Johnson, Biologix, Eli Lilly. Research support: Abbvie, AstraZeneca. Other authors declare no conflict of interest with this manuscript.

Similar articles

See all similar articles

References

    1. Kurtin S. Myeloid Toxicity of Cancer Treatment. J. Adv. Pract. Oncol. 2012;3:209–224. - PMC - PubMed
    1. Crawford J., Cella D., Cleeland C.S., Cremieux P., Demetri G.D., Sarokhan B.J., Slavin M.B., Glaspy J.A. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888–895. doi: 10.1002/cncr.10763. - DOI - PubMed
    1. Lalami Y., Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. Crit. Rev. Oncol. Hematol. 2017;120:163–179. doi: 10.1016/j.critrevonc.2017.11.005. - DOI - PubMed
    1. Lyman G.H., Dale D.C., Culakova E., Poniewierki M.S., Wolff D.A., Kuderer N.M., Huang M., Crawford J. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: A systematic review and meta-analysis of randomized controlled trials. Ann. Oncol. 2013;24:2475–2484. doi: 10.1093/annonc/mdt226. - DOI - PMC - PubMed
    1. Schiffer C.A., Bohlke K., Delaney M., Hume H., Magdalinski A.J., McCullough J.J., Omel J.L., Rainey J.M., Rebulla P., Rowley S.D., et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 2018;36:283–299. doi: 10.1200/JCO.2017.76.1734. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources